Skip to main content
Erschienen in: Clinical Journal of Gastroenterology 5/2019

12.04.2019 | Clinical Review

Vascular syndromes in liver cirrhosis

verfasst von: Botros Shenoda, Joseph Boselli

Erschienen in: Clinical Journal of Gastroenterology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Liver cirrhosis is associated with multiple vascular syndromes affecting almost all body systems. Many of these syndromes are directly related to impaired liver function and sometimes reversible after liver transplantation while others arise secondary to portal hypertension and ascites. Altered expression of angiogenic and vasoactive compounds (most importantly nitric oxide), endothelial dysfunction, dysregulated neurohormonal control, and systemic inflammatory state play differential roles in mediating homeostatic instability and abnormal vasogenic response. Important vascular features encountered in liver disease include portal hypertension, splanchnic overflow, abnormal angiogenesis and shunts, portopulmonary syndrome, hepatopulmonary syndrome, and systemic hyperdynamic circulation. Redistribution of effective circulatory volume deviating from vital organs and pooling in splanchnic circulation is also encountered in liver patients which may lead to devastating outcomes as hepatorenal syndrome. Etiologically, vascular syndromes are not isolated phenomena and vascular dysfunction in one system may lead to the development of another in a different system. This review focuses on understanding the pathophysiological factors underlying vascular syndromes related to chronic liver disease and the potential links among them. Many of these syndromes are associated with high mortality, thus it is crucial to look for early biomarkers for these syndromes and develop novel preventive and therapeutic strategies.
Literatur
1.
Zurück zum Zitat Moller S, Henriksen JH, Bendtsen F. Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects. World J Gastroenterol. 2014;20:15499–517.PubMedPubMedCentralCrossRef Moller S, Henriksen JH, Bendtsen F. Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects. World J Gastroenterol. 2014;20:15499–517.PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Gines P, Cardenas A. The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis. 2008;28:43–58.PubMedCrossRef Gines P, Cardenas A. The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis. 2008;28:43–58.PubMedCrossRef
3.
Zurück zum Zitat Nunes H, Lebrec D, Mazmanian M, et al. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med. 2001;164:879–85.PubMedCrossRef Nunes H, Lebrec D, Mazmanian M, et al. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med. 2001;164:879–85.PubMedCrossRef
4.
Zurück zum Zitat Carter EP, Hartsfield CL, Miyazono M, et al. Regulation of heme oxygenase-1 by nitric oxide during hepatopulmonary syndrome. Am J Physiol Lung Cell Mol Physiol. 2002;283:L346-53.PubMedCrossRef Carter EP, Hartsfield CL, Miyazono M, et al. Regulation of heme oxygenase-1 by nitric oxide during hepatopulmonary syndrome. Am J Physiol Lung Cell Mol Physiol. 2002;283:L346-53.PubMedCrossRef
5.
Zurück zum Zitat Zhang HY, Han DW, Wang XG, et al. Experimental study on the role of endotoxin in the development of hepatopulmonary syndrome. World J Gastroenterol. 2005;11:567–72.PubMedPubMedCentralCrossRef Zhang HY, Han DW, Wang XG, et al. Experimental study on the role of endotoxin in the development of hepatopulmonary syndrome. World J Gastroenterol. 2005;11:567–72.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Zhang HY, Han DW, Zhao ZF, et al. Multiple pathogenic factor-induced complications of cirrhosis in rats: a new model of hepatopulmonary syndrome with intestinal endotoxemia. World J Gastroenterol. 2007;13:3500–7.PubMedPubMedCentralCrossRef Zhang HY, Han DW, Zhao ZF, et al. Multiple pathogenic factor-induced complications of cirrhosis in rats: a new model of hepatopulmonary syndrome with intestinal endotoxemia. World J Gastroenterol. 2007;13:3500–7.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Henriksen JH, Bendtsen F, Sorensen TI, et al. Reduced central blood volume in cirrhosis. Gastroenterology. 1989;97:1506–13.PubMedCrossRef Henriksen JH, Bendtsen F, Sorensen TI, et al. Reduced central blood volume in cirrhosis. Gastroenterology. 1989;97:1506–13.PubMedCrossRef
8.
Zurück zum Zitat Gatta A, Bolognesi M, Merkel C. Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis. Mol Aspects Med. 2008;29:119–29.PubMedCrossRef Gatta A, Bolognesi M, Merkel C. Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis. Mol Aspects Med. 2008;29:119–29.PubMedCrossRef
9.
Zurück zum Zitat Gines P, Fernandez J, Durand F, et al. Management of critically-ill cirrhotic patients. J Hepatol. 2012;56(Suppl 1):13–24.CrossRef Gines P, Fernandez J, Durand F, et al. Management of critically-ill cirrhotic patients. J Hepatol. 2012;56(Suppl 1):13–24.CrossRef
10.
Zurück zum Zitat Zheng Y, Song WP, Zhao YY, et al. A new strategy to establish a hepatopulmonary syndrome model in rats by inducing abdominal compartment syndrome in the presence of cirrhosis. Zhonghua Gan Zang Bing Za Zhi. 2013;21:138–41.PubMed Zheng Y, Song WP, Zhao YY, et al. A new strategy to establish a hepatopulmonary syndrome model in rats by inducing abdominal compartment syndrome in the presence of cirrhosis. Zhonghua Gan Zang Bing Za Zhi. 2013;21:138–41.PubMed
11.
Zurück zum Zitat Roberts KE, Fallon MB, Krowka MJ, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med. 2009;179:835–42.PubMedPubMedCentralCrossRef Roberts KE, Fallon MB, Krowka MJ, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med. 2009;179:835–42.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Moller S, Henriksen JH. Cardiovascular complications of cirrhosis. Postgrad Med J. 2009;85:44–54.PubMed Moller S, Henriksen JH. Cardiovascular complications of cirrhosis. Postgrad Med J. 2009;85:44–54.PubMed
13.
Zurück zum Zitat Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29:1690–7.PubMedCrossRef Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29:1690–7.PubMedCrossRef
14.
Zurück zum Zitat Gracia-Sancho J, Lavina B, Rodriguez-Vilarrupla A, et al. Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. J Hepatol. 2007;47:220–7.PubMedCrossRef Gracia-Sancho J, Lavina B, Rodriguez-Vilarrupla A, et al. Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. J Hepatol. 2007;47:220–7.PubMedCrossRef
15.
Zurück zum Zitat Carrion JA, Navasa M, Bosch J, et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl. 2006;12:1791–8.PubMedCrossRef Carrion JA, Navasa M, Bosch J, et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl. 2006;12:1791–8.PubMedCrossRef
16.
Zurück zum Zitat Nagula S, Jain D, Groszmann RJ, et al. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol. 2006;44:111–7.PubMedCrossRef Nagula S, Jain D, Groszmann RJ, et al. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol. 2006;44:111–7.PubMedCrossRef
17.
Zurück zum Zitat Garcia-Tsao G. Portal hypertension. Curr Opin Gastroenterol. 2006;22:254–62.PubMed Garcia-Tsao G. Portal hypertension. Curr Opin Gastroenterol. 2006;22:254–62.PubMed
18.
Zurück zum Zitat Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology. 1997;25:2–5.PubMedCrossRef Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology. 1997;25:2–5.PubMedCrossRef
19.
Zurück zum Zitat Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol. 1985;1:325–37.PubMedCrossRef Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol. 1985;1:325–37.PubMedCrossRef
20.
Zurück zum Zitat Rockey DC. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology. 2000;118:1261–5.PubMedCrossRef Rockey DC. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology. 2000;118:1261–5.PubMedCrossRef
21.
Zurück zum Zitat Garcia-Pagan JC, Bosch J, Rodes J. The role of vasoactive mediators in portal hypertension. Semin Gastrointest Dis. 1995;6:140–7.PubMed Garcia-Pagan JC, Bosch J, Rodes J. The role of vasoactive mediators in portal hypertension. Semin Gastrointest Dis. 1995;6:140–7.PubMed
22.
Zurück zum Zitat Jimenez W, Rodes J. Impaired responsiveness to endogenous vasoconstrictors and endothelium-derived vasoactive factors in cirrhosis. Gastroenterology. 1994;107:1201–3.PubMedCrossRef Jimenez W, Rodes J. Impaired responsiveness to endogenous vasoconstrictors and endothelium-derived vasoactive factors in cirrhosis. Gastroenterology. 1994;107:1201–3.PubMedCrossRef
23.
Zurück zum Zitat Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003;200:500–3.PubMedCrossRef Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003;200:500–3.PubMedCrossRef
24.
Zurück zum Zitat Pinzani M, Failli P, Ruocco C, et al. Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest. 1992;90:642–6.PubMedPubMedCentralCrossRef Pinzani M, Failli P, Ruocco C, et al. Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest. 1992;90:642–6.PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Laragh JH, Angers M, Kelly WG, et al. Hypotensive agents and pressor substances. The effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man. JAMA. 1960;174:234–40.PubMedCrossRef Laragh JH, Angers M, Kelly WG, et al. Hypotensive agents and pressor substances. The effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man. JAMA. 1960;174:234–40.PubMedCrossRef
26.
Zurück zum Zitat Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology. 1999;29:334–9.PubMedCrossRef Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology. 1999;29:334–9.PubMedCrossRef
27.
Zurück zum Zitat Bhunchet E, Fujieda K. Capillarization and venularization of hepatic sinusoids in porcine serum-induced rat liver fibrosis: a mechanism to maintain liver blood flow. Hepatology. 1993;18:1450–8.PubMedCrossRef Bhunchet E, Fujieda K. Capillarization and venularization of hepatic sinusoids in porcine serum-induced rat liver fibrosis: a mechanism to maintain liver blood flow. Hepatology. 1993;18:1450–8.PubMedCrossRef
28.
Zurück zum Zitat Iwakiri Y, Shah V, Rockey DC. Vascular pathobiology in chronic liver disease and cirrhosis—current status and future directions. J Hepatol. 2014;61:912–24.PubMedPubMedCentralCrossRef Iwakiri Y, Shah V, Rockey DC. Vascular pathobiology in chronic liver disease and cirrhosis—current status and future directions. J Hepatol. 2014;61:912–24.PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Gupta TK, Toruner M, Chung MK, et al. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology. 1998;28:926–31.PubMedCrossRef Gupta TK, Toruner M, Chung MK, et al. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology. 1998;28:926–31.PubMedCrossRef
30.
Zurück zum Zitat Matei V, Rodriguez-Vilarrupla A, Deulofeu R, et al. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology. 2006;44:44–52.PubMedCrossRef Matei V, Rodriguez-Vilarrupla A, Deulofeu R, et al. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology. 2006;44:44–52.PubMedCrossRef
31.
Zurück zum Zitat Ding BS, Nolan DJ, Butler JM, et al. Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature. 2010;468:310–5.PubMedPubMedCentralCrossRef Ding BS, Nolan DJ, Butler JM, et al. Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature. 2010;468:310–5.PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Wang L, Wang X, Xie G, et al. Liver sinusoidal endothelial cell progenitor cells promote liver regeneration in rats. J Clin Invest. 2012;122:1567–73.PubMedPubMedCentralCrossRef Wang L, Wang X, Xie G, et al. Liver sinusoidal endothelial cell progenitor cells promote liver regeneration in rats. J Clin Invest. 2012;122:1567–73.PubMedPubMedCentralCrossRef
33.
34.
Zurück zum Zitat Hou MC, Cahill PA, Zhang S, et al. Enhanced cyclooxygenase-1 expression within the superior mesenteric artery of portal hypertensive rats: role in the hyperdynamic circulation. Hepatology. 1998;27:20–7.PubMedCrossRef Hou MC, Cahill PA, Zhang S, et al. Enhanced cyclooxygenase-1 expression within the superior mesenteric artery of portal hypertensive rats: role in the hyperdynamic circulation. Hepatology. 1998;27:20–7.PubMedCrossRef
35.
Zurück zum Zitat Benzel I, Bansal A, Browning BL, et al. Interactions among genes in the ErbB-Neuregulin signalling network are associated with increased susceptibility to schizophrenia. Behav Brain Funct. 2007;3:31.PubMedPubMedCentralCrossRef Benzel I, Bansal A, Browning BL, et al. Interactions among genes in the ErbB-Neuregulin signalling network are associated with increased susceptibility to schizophrenia. Behav Brain Funct. 2007;3:31.PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Graupera M, Garcia-Pagan JC, Pares M, et al. Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. J Hepatol. 2003;39:515–21.PubMedCrossRef Graupera M, Garcia-Pagan JC, Pares M, et al. Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. J Hepatol. 2003;39:515–21.PubMedCrossRef
37.
Zurück zum Zitat Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology. 1998;114:344–51.PubMedCrossRef Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology. 1998;114:344–51.PubMedCrossRef
38.
Zurück zum Zitat Shah V, Toruner M, Haddad F, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology. 1999;117:1222–8.PubMedCrossRef Shah V, Toruner M, Haddad F, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology. 1999;117:1222–8.PubMedCrossRef
39.
Zurück zum Zitat Clemens MG. Does altered regulation of ecNOS in sinusoidal endothelial cells determine increased intrahepatic resistance leading to portal hypertension? Hepatology. 1998;27:1745–7.PubMedCrossRef Clemens MG. Does altered regulation of ecNOS in sinusoidal endothelial cells determine increased intrahepatic resistance leading to portal hypertension? Hepatology. 1998;27:1745–7.PubMedCrossRef
40.
Zurück zum Zitat Thabut D, Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol. 2010;53:976–80.PubMedCrossRef Thabut D, Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol. 2010;53:976–80.PubMedCrossRef
41.
Zurück zum Zitat Taura K, De Minicis S, Seki E, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology. 2008;135:1729–38.PubMedCrossRef Taura K, De Minicis S, Seki E, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology. 2008;135:1729–38.PubMedCrossRef
42.
Zurück zum Zitat De Spiegelaere W, Cornillie P, Van den Broeck W, et al. Angiopoietins differentially influence in vitro angiogenesis by endothelial cells of different origin. Clin Hemorheol Microcirc. 2011;48:15–27.PubMed De Spiegelaere W, Cornillie P, Van den Broeck W, et al. Angiopoietins differentially influence in vitro angiogenesis by endothelial cells of different origin. Clin Hemorheol Microcirc. 2011;48:15–27.PubMed
44.
Zurück zum Zitat Bolognesi M, Di Pascoli M, Verardo A, et al. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis. World J Gastroenterol. 2014;20:2555–63.PubMedPubMedCentralCrossRef Bolognesi M, Di Pascoli M, Verardo A, et al. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis. World J Gastroenterol. 2014;20:2555–63.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol. 1983;244:G52–7.PubMed Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol. 1983;244:G52–7.PubMed
46.
Zurück zum Zitat Fernandez M, Mejias M, Angermayr B, et al. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol. 2005;43:98–103.PubMedCrossRef Fernandez M, Mejias M, Angermayr B, et al. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol. 2005;43:98–103.PubMedCrossRef
47.
Zurück zum Zitat Sherwin R, Joshi P, Hendler R, et al. Hyperglucagonemia in Laennec’s cirrhosis. The role of portal-systemic shunting. N Engl J Med. 1974;290:239–42.PubMedCrossRef Sherwin R, Joshi P, Hendler R, et al. Hyperglucagonemia in Laennec’s cirrhosis. The role of portal-systemic shunting. N Engl J Med. 1974;290:239–42.PubMedCrossRef
48.
Zurück zum Zitat Sogni P, Moreau R, Gadano A, et al. The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension. J Hepatol. 1995;23:218–24.PubMedCrossRef Sogni P, Moreau R, Gadano A, et al. The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension. J Hepatol. 1995;23:218–24.PubMedCrossRef
49.
Zurück zum Zitat Hori N, Okanoue T, Sawa Y, et al. Role of calcitonin gene-related peptide in the vascular system on the development of the hyperdynamic circulation in conscious cirrhotic rats. J Hepatol. 1997;26:1111–9.PubMedCrossRef Hori N, Okanoue T, Sawa Y, et al. Role of calcitonin gene-related peptide in the vascular system on the development of the hyperdynamic circulation in conscious cirrhotic rats. J Hepatol. 1997;26:1111–9.PubMedCrossRef
50.
Zurück zum Zitat Fernandez-Rodriguez CM, Prada IR, Prieto J, et al. Circulating adrenomedullin in cirrhosis: relationship to hyperdynamic circulation. J Hepatol. 1998;29:250–6.PubMedCrossRef Fernandez-Rodriguez CM, Prada IR, Prieto J, et al. Circulating adrenomedullin in cirrhosis: relationship to hyperdynamic circulation. J Hepatol. 1998;29:250–6.PubMedCrossRef
51.
Zurück zum Zitat Perez-Ruiz M, Ros J, Morales-Ruiz M, et al. Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: regulation by cytokines and bacterial lipopolysaccharide. Hepatology. 1999;29:1057–63.PubMedCrossRef Perez-Ruiz M, Ros J, Morales-Ruiz M, et al. Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: regulation by cytokines and bacterial lipopolysaccharide. Hepatology. 1999;29:1057–63.PubMedCrossRef
52.
Zurück zum Zitat Bolognesi M, Sacerdoti D, Di Pascoli M, et al. Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites. Gut. 2005;54:1630–6.PubMedPubMedCentralCrossRef Bolognesi M, Sacerdoti D, Di Pascoli M, et al. Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites. Gut. 2005;54:1630–6.PubMedPubMedCentralCrossRef
54.
Zurück zum Zitat Grace JA, Klein S, Herath CB, et al. Activation of the MAS receptor by angiotensin-(1–7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis. Gastroenterology. 2013;145:874–84 e5.PubMedCrossRef Grace JA, Klein S, Herath CB, et al. Activation of the MAS receptor by angiotensin-(1–7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis. Gastroenterology. 2013;145:874–84 e5.PubMedCrossRef
55.
Zurück zum Zitat Atucha NM, Shah V, Garcia-Cardena G, et al. Role of endothelium in the abnormal response of mesenteric vessels in rats with portal hypertension and liver cirrhosis. Gastroenterology. 1996;111:1627–32.PubMedCrossRef Atucha NM, Shah V, Garcia-Cardena G, et al. Role of endothelium in the abnormal response of mesenteric vessels in rats with portal hypertension and liver cirrhosis. Gastroenterology. 1996;111:1627–32.PubMedCrossRef
56.
Zurück zum Zitat Cahill PA, Redmond EM, Hodges R, et al. Increased endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats. J Hepatol. 1996;25:370–8.PubMedCrossRef Cahill PA, Redmond EM, Hodges R, et al. Increased endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats. J Hepatol. 1996;25:370–8.PubMedCrossRef
57.
Zurück zum Zitat Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601–5.PubMedCrossRef Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601–5.PubMedCrossRef
58.
Zurück zum Zitat Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest. 1999;104:1223–33.PubMedPubMedCentralCrossRef Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest. 1999;104:1223–33.PubMedPubMedCentralCrossRef
59.
Zurück zum Zitat Hamilton G, Phing RC, Hutton RA, et al. The relationship between prostacyclin activity and pressure in the portal vein. Hepatology. 1982;2:236–42.PubMedCrossRef Hamilton G, Phing RC, Hutton RA, et al. The relationship between prostacyclin activity and pressure in the portal vein. Hepatology. 1982;2:236–42.PubMedCrossRef
60.
Zurück zum Zitat Bruix J, Bosch J, Kravetz D, et al. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology. 1985;88:430–5.PubMedCrossRef Bruix J, Bosch J, Kravetz D, et al. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology. 1985;88:430–5.PubMedCrossRef
61.
Zurück zum Zitat Cahill PA, Redmond EM, Sitzmann JV. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther. 2001;89:273–93.PubMedCrossRef Cahill PA, Redmond EM, Sitzmann JV. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther. 2001;89:273–93.PubMedCrossRef
62.
Zurück zum Zitat Barriere E, Tazi KA, Rona JP, et al. Evidence for an endothelium-derived hyperpolarizing factor in the superior mesenteric artery from rats with cirrhosis. Hepatology. 2000;32:935–41.PubMedCrossRef Barriere E, Tazi KA, Rona JP, et al. Evidence for an endothelium-derived hyperpolarizing factor in the superior mesenteric artery from rats with cirrhosis. Hepatology. 2000;32:935–41.PubMedCrossRef
63.
Zurück zum Zitat Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43:121-31.CrossRef Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43:121-31.CrossRef
64.
Zurück zum Zitat Chen YC, Gines P, Yang J, et al. Increased vascular heme oxygenase-1 expression contributes to arterial vasodilation in experimental cirrhosis in rats. Hepatology. 2004;39:1075–87.PubMedCrossRef Chen YC, Gines P, Yang J, et al. Increased vascular heme oxygenase-1 expression contributes to arterial vasodilation in experimental cirrhosis in rats. Hepatology. 2004;39:1075–87.PubMedCrossRef
65.
Zurück zum Zitat Bolognesi M, Sacerdoti D, Piva A, et al. Carbon monoxide-mediated activation of large-conductance calcium-activated potassium channels contributes to mesenteric vasodilatation in cirrhotic rats. J Pharmacol Exp Ther. 2007;321:187–94.PubMedCrossRef Bolognesi M, Sacerdoti D, Piva A, et al. Carbon monoxide-mediated activation of large-conductance calcium-activated potassium channels contributes to mesenteric vasodilatation in cirrhotic rats. J Pharmacol Exp Ther. 2007;321:187–94.PubMedCrossRef
66.
Zurück zum Zitat Batkai S, Jarai Z, Wagner JA, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med. 2001;7:827–32.PubMedCrossRef Batkai S, Jarai Z, Wagner JA, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med. 2001;7:827–32.PubMedCrossRef
67.
Zurück zum Zitat Moezi L, Gaskari SA, Liu H, et al. Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors. Br J Pharmacol. 2006;149:898–908.PubMedPubMedCentralCrossRef Moezi L, Gaskari SA, Liu H, et al. Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors. Br J Pharmacol. 2006;149:898–908.PubMedPubMedCentralCrossRef
68.
Zurück zum Zitat Ros J, Claria J, To-Figueras J, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology. 2002;122:85–93.PubMedCrossRef Ros J, Claria J, To-Figueras J, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology. 2002;122:85–93.PubMedCrossRef
69.
Zurück zum Zitat Moleda L, Trebicka J, Dietrich P, et al. Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction. Gut. 2011;60:1122–32.PubMedCrossRef Moleda L, Trebicka J, Dietrich P, et al. Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction. Gut. 2011;60:1122–32.PubMedCrossRef
70.
Zurück zum Zitat Trebicka J, Leifeld L, Hennenberg M, et al. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology. 2008;47:1264–76.PubMedCrossRef Trebicka J, Leifeld L, Hennenberg M, et al. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology. 2008;47:1264–76.PubMedCrossRef
71.
Zurück zum Zitat Acosta F, Sansano T, Palenciano CG, et al. Differential response of the systemic and pulmonary circulation related to disease severity of cirrhosis. Transplant Proc. 2005;37:3889–3890. Acosta F, Sansano T, Palenciano CG, et al. Differential response of the systemic and pulmonary circulation related to disease severity of cirrhosis. Transplant Proc. 2005;37:3889–3890.
72.
Zurück zum Zitat Blendis L, Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther. 2001;89:221–31.PubMedCrossRef Blendis L, Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther. 2001;89:221–31.PubMedCrossRef
73.
Zurück zum Zitat Bosch J, Arroyo V, Betriu A, et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology. 1980;78:92–9.PubMedCrossRef Bosch J, Arroyo V, Betriu A, et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology. 1980;78:92–9.PubMedCrossRef
74.
Zurück zum Zitat Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology. 1989;97:1304–12.PubMedCrossRef Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology. 1989;97:1304–12.PubMedCrossRef
75.
Zurück zum Zitat Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151–7.PubMedCrossRef Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151–7.PubMedCrossRef
76.
Zurück zum Zitat Claria J, Jimenez W, Arroyo V, et al. Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology. 1991;100:494–501.PubMedCrossRef Claria J, Jimenez W, Arroyo V, et al. Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology. 1991;100:494–501.PubMedCrossRef
77.
Zurück zum Zitat Bernardi M, Moreau R, Angeli P, et al. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63:1272–84.PubMedCrossRef Bernardi M, Moreau R, Angeli P, et al. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63:1272–84.PubMedCrossRef
78.
Zurück zum Zitat Tazi KA, Barriere E, Moreau R, et al. Role of shear stress in aortic eNOS up-regulation in rats with biliary cirrhosis. Gastroenterology. 2002;122:1869–77.PubMedCrossRef Tazi KA, Barriere E, Moreau R, et al. Role of shear stress in aortic eNOS up-regulation in rats with biliary cirrhosis. Gastroenterology. 2002;122:1869–77.PubMedCrossRef
79.
Zurück zum Zitat Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014;60:197–209.PubMedCrossRef Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014;60:197–209.PubMedCrossRef
80.
Zurück zum Zitat Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877–87.PubMedCrossRef Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877–87.PubMedCrossRef
81.
Zurück zum Zitat Bauer TM, Schwacha H, Steinbruckner B, et al. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol. 2002;97:2364–70.PubMedCrossRef Bauer TM, Schwacha H, Steinbruckner B, et al. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol. 2002;97:2364–70.PubMedCrossRef
82.
Zurück zum Zitat Gandoura S, Weiss E, Rautou PE, et al. Gene- and exon-expression profiling reveals an extensive LPS-induced response in immune cells in patients with cirrhosis. J Hepatol. 2013;58:936–48.PubMedCrossRef Gandoura S, Weiss E, Rautou PE, et al. Gene- and exon-expression profiling reveals an extensive LPS-induced response in immune cells in patients with cirrhosis. J Hepatol. 2013;58:936–48.PubMedCrossRef
83.
Zurück zum Zitat Wiest R, Cadelina G, Milstien S, et al. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology. 2003;38:1508–15.PubMedCrossRef Wiest R, Cadelina G, Milstien S, et al. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology. 2003;38:1508–15.PubMedCrossRef
84.
Zurück zum Zitat Ohta M, Tarnawski AS, Itani R, et al. Tumor necrosis factor alpha regulates nitric oxide synthase expression in portal hypertensive gastric mucosa of rats. Hepatology. 1998;27:906–13.PubMedCrossRef Ohta M, Tarnawski AS, Itani R, et al. Tumor necrosis factor alpha regulates nitric oxide synthase expression in portal hypertensive gastric mucosa of rats. Hepatology. 1998;27:906–13.PubMedCrossRef
85.
Zurück zum Zitat Riordan SM, Skinner N, Nagree A, et al. Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology. 2003;37:1154–64.PubMedCrossRef Riordan SM, Skinner N, Nagree A, et al. Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology. 2003;37:1154–64.PubMedCrossRef
86.
Zurück zum Zitat Tazi KA, Moreau R, Herve P, et al. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling. Gastroenterology. 2005;129:303–14.PubMedCrossRef Tazi KA, Moreau R, Herve P, et al. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling. Gastroenterology. 2005;129:303–14.PubMedCrossRef
87.
Zurück zum Zitat Chin-Dusting JP, Rasaratnam B, Jennings GL, et al. Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis. Ann Intern Med. 1997;127:985–8.PubMedCrossRef Chin-Dusting JP, Rasaratnam B, Jennings GL, et al. Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis. Ann Intern Med. 1997;127:985–8.PubMedCrossRef
88.
Zurück zum Zitat Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology. 1995;108:761–7.PubMedCrossRef Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology. 1995;108:761–7.PubMedCrossRef
89.
Zurück zum Zitat Munoz J, Albillos A, Perez-Paramo M, et al. Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats. Am J Physiol. 1999;276:G687-93.PubMed Munoz J, Albillos A, Perez-Paramo M, et al. Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats. Am J Physiol. 1999;276:G687-93.PubMed
90.
Zurück zum Zitat Lopez-Talavera JC, Cadelina G, Olchowski J, et al. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology. 1996;23:1616–21.PubMed Lopez-Talavera JC, Cadelina G, Olchowski J, et al. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology. 1996;23:1616–21.PubMed
91.
Zurück zum Zitat Lopez-Talavera JC, Levitzki A, Martinez M, et al. Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites. J Clin Invest. 1997;100:664–70.PubMedPubMedCentralCrossRef Lopez-Talavera JC, Levitzki A, Martinez M, et al. Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites. J Clin Invest. 1997;100:664–70.PubMedPubMedCentralCrossRef
92.
Zurück zum Zitat Niederberger M, Martin PY, Gines P, et al. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology. 1995;109:1624–30.PubMedCrossRef Niederberger M, Martin PY, Gines P, et al. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology. 1995;109:1624–30.PubMedCrossRef
93.
Zurück zum Zitat Newby DE, Hayes PC. Hyperdynamic circulation in liver cirrhosis: not peripheral vasodilatation but ‘splanchnic steal’. QJM. 2002;95:827–30.PubMedCrossRef Newby DE, Hayes PC. Hyperdynamic circulation in liver cirrhosis: not peripheral vasodilatation but ‘splanchnic steal’. QJM. 2002;95:827–30.PubMedCrossRef
94.
Zurück zum Zitat Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42:439–47.PubMedCrossRef Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42:439–47.PubMedCrossRef
95.
Zurück zum Zitat Wiese S, Hove JD, Bendtsen F, et al. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol. 2014;11:177–86.PubMedCrossRef Wiese S, Hove JD, Bendtsen F, et al. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol. 2014;11:177–86.PubMedCrossRef
96.
Zurück zum Zitat Merkel C, Gatta A, Milani L, et al. Intrarenal blood flow, circulation time, and cortical vascular volume in patients with cirrhosis. Scand J Gastroenterol. 1981;16:775–80.PubMedCrossRef Merkel C, Gatta A, Milani L, et al. Intrarenal blood flow, circulation time, and cortical vascular volume in patients with cirrhosis. Scand J Gastroenterol. 1981;16:775–80.PubMedCrossRef
97.
Zurück zum Zitat Almdal T, Schroeder T, Ranek L. Cerebral blood flow and liver function in patients with encephalopathy due to acute and chronic liver diseases. Scand J Gastroenterol. 1989;24:299–303.PubMedCrossRef Almdal T, Schroeder T, Ranek L. Cerebral blood flow and liver function in patients with encephalopathy due to acute and chronic liver diseases. Scand J Gastroenterol. 1989;24:299–303.PubMedCrossRef
98.
Zurück zum Zitat Maroto A, Gines P, Arroyo V, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology. 1993;17:788–93.PubMed Maroto A, Gines P, Arroyo V, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology. 1993;17:788–93.PubMed
99.
Zurück zum Zitat Rajekar H, Chawla Y. Terlipressin in hepatorenal syndrome: evidence for present indications. J Gastroenterol Hepatol. 2011;26(Suppl 1):109–14.PubMedCrossRef Rajekar H, Chawla Y. Terlipressin in hepatorenal syndrome: evidence for present indications. J Gastroenterol Hepatol. 2011;26(Suppl 1):109–14.PubMedCrossRef
100.
Zurück zum Zitat Groszmann RJ, Abraldes JG. Portal hypertension: from bedside to bench. J Clin Gastroenterol. 2005;39:125-30.CrossRef Groszmann RJ, Abraldes JG. Portal hypertension: from bedside to bench. J Clin Gastroenterol. 2005;39:125-30.CrossRef
101.
Zurück zum Zitat Bosch J. Vascular deterioration in cirrhosis: the big picture. J Clin Gastroenterol. 2007;41(Suppl 3):247-53. Bosch J. Vascular deterioration in cirrhosis: the big picture. J Clin Gastroenterol. 2007;41(Suppl 3):247-53.
102.
Zurück zum Zitat Huang HC, Haq O, Utsumi T, et al. Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure. J Cell Mol Med. 2012;16:1125–33.PubMedPubMedCentralCrossRef Huang HC, Haq O, Utsumi T, et al. Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure. J Cell Mol Med. 2012;16:1125–33.PubMedPubMedCentralCrossRef
103.
Zurück zum Zitat Fernandez M, Vizzutti F, Garcia-Pagan JC, et al. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology. 2004;126:886–94.PubMedCrossRef Fernandez M, Vizzutti F, Garcia-Pagan JC, et al. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology. 2004;126:886–94.PubMedCrossRef
104.
Zurück zum Zitat Van Steenkiste C, Geerts A, Vanheule E, et al. Role of placental growth factor in mesenteric neoangiogenesis in a mouse model of portal hypertension. Gastroenterology. 2009;137:2112-24 e1–6. Van Steenkiste C, Geerts A, Vanheule E, et al. Role of placental growth factor in mesenteric neoangiogenesis in a mouse model of portal hypertension. Gastroenterology. 2009;137:2112-24 e1–6.
105.
Zurück zum Zitat Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229–36.PubMedCrossRef Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229–36.PubMedCrossRef
106.
Zurück zum Zitat Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Int Ascites Club Hepatol. 1996;23:164–76. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Int Ascites Club Hepatol. 1996;23:164–76.
107.
Zurück zum Zitat Durand F, Graupera I, Gines P, et al. Pathogenesis of hepatorenal syndrome: implications for therapy. Am J Kidney Dis. 2016;67:318–28.PubMedCrossRef Durand F, Graupera I, Gines P, et al. Pathogenesis of hepatorenal syndrome: implications for therapy. Am J Kidney Dis. 2016;67:318–28.PubMedCrossRef
108.
Zurück zum Zitat Epstein M, Berk DP, Hollenberg NK, et al. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med. 1970;49:175–85.PubMedCrossRef Epstein M, Berk DP, Hollenberg NK, et al. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med. 1970;49:175–85.PubMedCrossRef
109.
Zurück zum Zitat Stadlbauer V, Wright GA, Banaji M, et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology. 2008;134:111–9.PubMedCrossRef Stadlbauer V, Wright GA, Banaji M, et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology. 2008;134:111–9.PubMedCrossRef
110.
Zurück zum Zitat Moore K, Wendon J, Frazer M, et al. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med. 1992;327:1774–8.PubMedCrossRef Moore K, Wendon J, Frazer M, et al. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med. 1992;327:1774–8.PubMedCrossRef
111.
Zurück zum Zitat Asbert M, Gines A, Gines P, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology. 1993;104:1485–91.PubMedCrossRef Asbert M, Gines A, Gines P, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology. 1993;104:1485–91.PubMedCrossRef
112.
Zurück zum Zitat Wong F, Moore K, Dingemanse J, et al. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology. 2008;47:160–8.PubMedCrossRef Wong F, Moore K, Dingemanse J, et al. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology. 2008;47:160–8.PubMedCrossRef
113.
Zurück zum Zitat La Villa G, Romanelli RG, Casini Raggi V, et al. Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology. 1992;16:156–61.PubMedCrossRef La Villa G, Romanelli RG, Casini Raggi V, et al. Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology. 1992;16:156–61.PubMedCrossRef
114.
Zurück zum Zitat Gines P, Jimenez W, Arroyo V, et al. Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology. 1988;8:636–42.PubMedCrossRef Gines P, Jimenez W, Arroyo V, et al. Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology. 1988;8:636–42.PubMedCrossRef
115.
Zurück zum Zitat Elia C, Graupera I, Barreto R, et al. Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: a case-control study. J Hepatol. 2015;63:593–600.PubMedCrossRef Elia C, Graupera I, Barreto R, et al. Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: a case-control study. J Hepatol. 2015;63:593–600.PubMedCrossRef
116.
Zurück zum Zitat Adebayo D, Morabito V, Davenport A, et al. Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int. 2015;87:509–15.PubMedCrossRef Adebayo D, Morabito V, Davenport A, et al. Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int. 2015;87:509–15.PubMedCrossRef
118.
Zurück zum Zitat Schraufnagel DE, Kay JM. Structural and pathologic changes in the lung vasculature in chronic liver disease. Clin Chest Med. 1996;17:1–15.PubMedCrossRef Schraufnagel DE, Kay JM. Structural and pathologic changes in the lung vasculature in chronic liver disease. Clin Chest Med. 1996;17:1–15.PubMedCrossRef
119.
120.
Zurück zum Zitat Rodriguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome–a liver-induced lung vascular disorder. N Engl J Med. 2008;358:2378–87.PubMedCrossRef Rodriguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome–a liver-induced lung vascular disorder. N Engl J Med. 2008;358:2378–87.PubMedCrossRef
121.
Zurück zum Zitat Rolla G, Brussino L, Colagrande P, et al. Exhaled nitric oxide and impaired oxygenation in cirrhotic patients before and after liver transplantation. Ann Intern Med. 1998;129:375–8.PubMedCrossRef Rolla G, Brussino L, Colagrande P, et al. Exhaled nitric oxide and impaired oxygenation in cirrhotic patients before and after liver transplantation. Ann Intern Med. 1998;129:375–8.PubMedCrossRef
122.
Zurück zum Zitat Tumgor G, Arikan C, Yuksekkaya HA, et al. Childhood cirrhosis, hepatopulmonary syndrome and liver transplantation. Pediatr Transplant. 2008;12:353–7.PubMedCrossRef Tumgor G, Arikan C, Yuksekkaya HA, et al. Childhood cirrhosis, hepatopulmonary syndrome and liver transplantation. Pediatr Transplant. 2008;12:353–7.PubMedCrossRef
123.
Zurück zum Zitat Rovin BH, Yoshiumura T, Tan L. Cytokine-induced production of monocyte chemoattractant protein-1 by cultured human mesangial cells. J Immunol. 1992;148:2148–53.PubMed Rovin BH, Yoshiumura T, Tan L. Cytokine-induced production of monocyte chemoattractant protein-1 by cultured human mesangial cells. J Immunol. 1992;148:2148–53.PubMed
124.
Zurück zum Zitat Carter D, Douglass JF, Cornellison CD, et al. Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. Biochemistry. 2002;41:6714–22.PubMedCrossRef Carter D, Douglass JF, Cornellison CD, et al. Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. Biochemistry. 2002;41:6714–22.PubMedCrossRef
125.
Zurück zum Zitat Arguedas MR, Drake BB, Kapoor A, et al. Carboxyhemoglobin levels in cirrhotic patients with and without hepatopulmonary syndrome. Gastroenterology. 2005;128:328–33.PubMedCrossRef Arguedas MR, Drake BB, Kapoor A, et al. Carboxyhemoglobin levels in cirrhotic patients with and without hepatopulmonary syndrome. Gastroenterology. 2005;128:328–33.PubMedCrossRef
126.
127.
Zurück zum Zitat Hortnagl H, Singer EA, Lenz K, et al. Substance P is markedly increased in plasma of patients with hepatic coma. Lancet. 1984;1:480–3.PubMedCrossRef Hortnagl H, Singer EA, Lenz K, et al. Substance P is markedly increased in plasma of patients with hepatic coma. Lancet. 1984;1:480–3.PubMedCrossRef
128.
Zurück zum Zitat Caramelo C, Fernandez-Gallardo S, Santos JC, et al. Increased levels of platelet-activating factor in blood from patients with cirrhosis of the liver. Eur J Clin Invest. 1987;17:7–11.PubMedCrossRef Caramelo C, Fernandez-Gallardo S, Santos JC, et al. Increased levels of platelet-activating factor in blood from patients with cirrhosis of the liver. Eur J Clin Invest. 1987;17:7–11.PubMedCrossRef
129.
Zurück zum Zitat Panos RJ, Baker SK. Mediators, cytokines, and growth factors in liver-lung interactions. Clin Chest Med. 1996;17:151–69.PubMedCrossRef Panos RJ, Baker SK. Mediators, cytokines, and growth factors in liver-lung interactions. Clin Chest Med. 1996;17:151–69.PubMedCrossRef
130.
Zurück zum Zitat Song JY, Choi JY, Ko JT, et al. Long-term aspirin therapy for hepatopulmonary syndrome. Pediatrics. 1996;97:917–20.PubMed Song JY, Choi JY, Ko JT, et al. Long-term aspirin therapy for hepatopulmonary syndrome. Pediatrics. 1996;97:917–20.PubMed
131.
Zurück zum Zitat Zhang J, Luo B, Tang L, et al. Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome. Gastroenterology. 2009;136:1070–80.PubMedCrossRef Zhang J, Luo B, Tang L, et al. Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome. Gastroenterology. 2009;136:1070–80.PubMedCrossRef
132.
Zurück zum Zitat Roberts KE, Kawut SM, Krowka MJ, et al. Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. Gastroenterology. 2010;139:130-9 e24.PubMedCrossRef Roberts KE, Kawut SM, Krowka MJ, et al. Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. Gastroenterology. 2010;139:130-9 e24.PubMedCrossRef
133.
Zurück zum Zitat Sussman NL, Kochar R, Fallon MB. Pulmonary complications in cirrhosis. Curr Opin Organ Transplant. 2011;16:281–8.PubMedCrossRef Sussman NL, Kochar R, Fallon MB. Pulmonary complications in cirrhosis. Curr Opin Organ Transplant. 2011;16:281–8.PubMedCrossRef
134.
Zurück zum Zitat Dickinson MG, Bartelds B, Borgdorff MA, et al. The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models. Am J Physiol Lung Cell Mol Physiol. 2013;305:L1–14.PubMedCrossRef Dickinson MG, Bartelds B, Borgdorff MA, et al. The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models. Am J Physiol Lung Cell Mol Physiol. 2013;305:L1–14.PubMedCrossRef
135.
Zurück zum Zitat Machicao VI, Balakrishnan M, Fallon MB. Pulmonary complications in chronic liver disease. Hepatology. 2014;59:1627–37.PubMedCrossRef Machicao VI, Balakrishnan M, Fallon MB. Pulmonary complications in chronic liver disease. Hepatology. 2014;59:1627–37.PubMedCrossRef
136.
Zurück zum Zitat Talwalkar JA, Swanson KL, Krowka MJ, et al. Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment. Gastroenterology. 2011;141:1673–9.PubMedCrossRef Talwalkar JA, Swanson KL, Krowka MJ, et al. Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment. Gastroenterology. 2011;141:1673–9.PubMedCrossRef
137.
138.
Zurück zum Zitat Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159:1925–32.PubMedCrossRef Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159:1925–32.PubMedCrossRef
139.
Zurück zum Zitat Battistini B, Dussault P. Biosynthesis, distribution and metabolism of endothelins in the pulmonary system. Pulm Pharmacol Ther. 1998;11:79–88.PubMedCrossRef Battistini B, Dussault P. Biosynthesis, distribution and metabolism of endothelins in the pulmonary system. Pulm Pharmacol Ther. 1998;11:79–88.PubMedCrossRef
140.
Zurück zum Zitat Luo B, Liu L, Tang L, et al. Increased pulmonary vascular endothelin B receptor expression and responsiveness to endothelin-1 in cirrhotic and portal hypertensive rats: a potential mechanism in experimental hepatopulmonary syndrome. J Hepatol. 2003;38:556–63.PubMedCrossRef Luo B, Liu L, Tang L, et al. Increased pulmonary vascular endothelin B receptor expression and responsiveness to endothelin-1 in cirrhotic and portal hypertensive rats: a potential mechanism in experimental hepatopulmonary syndrome. J Hepatol. 2003;38:556–63.PubMedCrossRef
Metadaten
Titel
Vascular syndromes in liver cirrhosis
verfasst von
Botros Shenoda
Joseph Boselli
Publikationsdatum
12.04.2019
Verlag
Springer Japan
Erschienen in
Clinical Journal of Gastroenterology / Ausgabe 5/2019
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-019-00956-0

Weitere Artikel der Ausgabe 5/2019

Clinical Journal of Gastroenterology 5/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.